Skip to content

A study to evaluate the efficacy of digestive enzymes, carminatives & probiotics in the management of infantile colic

To evaluate the efficacy of digestive enzymes, carminatives & probiotics in the management of infantile colic in a tertiary care hospital in South India - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/11/060337
Enrollment
40
Registered
2023-11-29
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K638- Other specified diseases of intestine

Interventions

Intervention1: Combination of Probiotic, Digestive enzymes Carminatives (Tummy soft drops): Each 5 ml contains Bacillus coagulans 500 million GBI-30, 6086 Alpha Amylase (1:800) 25mg Pepsin (1:

Sponsors

Jhaver Research Foundation
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Infants (age 3 months to 1 year) fulfilling the Rome-IV diagnostic criteria for infantile colic with no evidence of acute/ chronic illness. 2. Rome-IV diagnostic for clinical research purposes, diagnosis of infantile colic also includes both of the following. 3. Caregiver reports infant has cried or fussed for three or more hours per day during three or more days in 7 days in a telephone or face-to-face screening interview; and 4. Total 24-h crying plus fussing in the selected group of infants is confirmed to be three h or more when measured by at least one prospectively kept 24-h behaviour diary. 5. Parents who report their infant crying excessively must be screened on an outpatient basis.

Exclusion criteria

Exclusion criteria: 1. Infants born before completing 34 weeks of gestation or birth weight 2. Infants with known gastrointestinal disorders, previous abdominal surgery, known galactosemia or diabetes mellitus will be excluded from the study. 3. Infants with severe dehydration. 4. Presence of systemic infections. 6. Infants with known immunocompromising morbidities. 7. Infants with severe acute malnutrition. 8. Infants with chronic or severe respiratory, cardiovascular, central nervous system, endocrine and other gastrointestinal disorders on clinical examination. 9. Infants with cystic fibrosis.

Design outcomes

Primary

MeasureTime frame
After a 5-day study, the primary outcome will be assessed by the clinical response which is defined as the percentage of infants achieving a reduction in the daily average crying time 50%Timepoint: 5-days

Secondary

MeasureTime frame
1. After a 5-day study, the secondary outcome will be assessed by the occurrence of adverse events (Milk regurgitation, vomiting, diarrhoea, constipation) following the administration of digestive enzymes, carminatives & probiotics and if any will be notified to the IPC and will be uploaded in Vigiflow. Parental satisfaction on a Likert scale through parental interviews after examining their daily records will be maintained in the dairyTimepoint: after 5 days

Countries

India

Contacts

Public ContactDr. G. Raj Kamal

Chengalpattu medical college

vijayapaed@gmail.com9444728805

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026